Shareholders “overwhelmingly” voted to approve Kimberly-Clark Corp.’s $48.7 billion acquisition of Summit-headquartered Kenvue, the companies jointly announced Jan. 29.
The health care giants first unveiled plans for the deal Nov. 3, 2025.
“This is an exciting milestone and advances our efforts to create a preeminent global health and wellness leader that will raise the standard of care for billions of people around the world and generate significant value for shareholders,” said Mike Hsu, Kimberly-Clark chairman and CEO.
Hsu also added that leaders from both companies are “collaborating well” on the integration efforts.
Next steps
The deal is expected to close in the second half of 2026, subject to regulatory approvals and other customary closing conditions.
The combined company will have its base at Kimberly-Clark’s current headquarters in Irving, Texas, according to the fall announcement. The company will “continue to have a significant presence in Kenvue’s locations,” the firms said at the time.
Approximately 96% of the shares present at Kimberly-Clark’s special meeting voted in favor of the transaction, the companies said in the most recent announcement, based on preliminary voting results. Approximately 99% of shares at Kenvue’s special meeting approved the merger. That figure represents approximately 77% of all outstanding shares.
Final vote results are subject to certification by the companies’ independent inspectors of elections and will be filed with the U.S. Securities and Exchange Commission.
Hsu will serve as chairman and CEO of the combined company. Additionally, three members of the Kenvue board of directors will join the Kimberly-Clark board.
Combining teams, portfolios
“We thank Kenvue shareholders for their strong support in approving our transaction with Kimberly-Clark,” said Kenvue CEO Kirk Perry. “As we continue to progress toward completing the transaction later this year, we remain confident in the growth opportunities ahead for the combined company as a global health and wellness leader.”
Kenvue opened its global headquarters in Summit in March 2025. Before that, the company separated from Johnson & Johnson in 2023.
Kenvue is considered the world’s largest pure-play consumer health company by revenue. Its portfolio includes Band-Aid, Neutrogena, Tylenol, Visine, Listerine, Aveeno and Rogaine.
“By bringing together our portfolios and teams, we can accelerate innovation, expand access to our trusted brands and deliver increased benefits to our customers and consumers worldwide. We look forward to reaching more consumers with our iconic brands as part of Kimberly-Clark,” Perry added.
The post Shareholders approve $48.7B Kimberly-Clark, Kenvue deal appeared first on NJBIZ.
